Jerome Webb Email & Phone Number

San Diego, CA, US

My role is disease state education to create/raise awareness, identify patients, and help speed diagnosis for SM- ( Systemic Mastocytosis). A rare hematologic “like” Mast Cell disease seen in roughly 1/10,000 people. My main call points right now are Allergy, Derm, and GI providers.Also “reactively” promote AYVAKIT ( Oral TKI ) to targeted high profile.

Cambridge, Cambridgeshire, GB

Needham, Massachusetts, US

Responsible for the launch and promotion of Copiktra ( Duvelisib ). A novel first in class dual PI3K inhibitor for use in CLL/SLL/FL.

• Primary area of responsibility will be to launch ERLEADA & promote Zytiga, Darzalex, & Yondelis into the Prostate Multiple Myeloma & Sarcoma spaces. My main charge will be to Expand usage of Zytiga in a very mature.
• 2017 Presidents Club Winner ​( No.2/145)
• Ranked No. 1 in the Region
• Instrumental in the development of KOL’s/Speakers in a largely “No-See” territory.
• Restored one of the lowest ranking territories in the Nation, to one of the top performing in my 1styear.

Leverkusen, North Rhine-Westphalia, DE

Pioneer in ushering in a new paradigm in the Biopharmaceutical industry, by introducing the first commercially available "Biosimilar" in the United States - Zarxio ( Filgrastim-sndz). Responsibilities will be to educate Oncology clinicians, Pharmacists and Nurses about Biosimilars. Increase patient access by providing a more affordable option to high cost.

Leverkusen, North Rhine-Westphalia, DE

• Responsible for promoting Xofigo (Radium 223) to Medical Oncology, Radiation Oncology, Urologists, and Nuclear Medicine for mCRPC.
• Instrumental in the successful launch and positioning of Xofigo.
• Produced 1st Xofigo injection in the Western Area
• Produced 1st patient ready site for Xofigo administration in Region
• Produced 13 patient ready sites for Xofigo administration in territory
• Ranked Number 1 in the Region every month since launch (Since May 2013)

Leverkusen, North Rhine-Westphalia, DE

Primary responsibility is the promotion of “Sancuso” ( A novel transdermal formulation of Granisetron) for the treatment of CINV in patients receiving Chemo/Radiation therapy. I augment the efforts of the Full-Time representative in the Oregon and SW Washington territory. Main “target” audience includes Medical Oncologists, Hematologists, and Radiation.

Wilmington, Delaware, US

My responsibilities included promoting “Jakafi”, the first ever “oral” Jak2 inhibitor approved by the FDA, for the treatment of Myelofibrosis. I was instrumental in the successful launch of this novel compound to Hematologists and Oncologists in Oregon and Idaho. I was also tasked with increasing overall awareness and educating staff on Myelofibrosis as a.

Primary responsibilities included the promotion of Xeloda and Kytril. My target audiences were the Medical Oncologists who treat solid tumors in the states of Oregon, Idaho and Utah. I was tasked with increasing usage, educating physicians and in-servicing the nursing staff about Xeloda’s utility as the “Oral” Chemotherapy of choice in Breast and Colon.

Responsible for promoting pharmaceuticals into the most competitive therapeutic arenas in the industry: Anti-Infectives, Anesthesia, Osteoporosis, Cardiovascular, Antiviral, Pain management, to name only a few. Main audiences are the physicians, nurses, and pharmacists that staff the community based clinics, hospitals, and teaching institutions in the.

Bs, Science/Pre-Med

Pre-Med